**Abstract**

Identification of novel molecular targets for treatment of epilepsy is required to solve the problems in its pharmacotherapy including side effects and tolerance in currently used antiepileptic drugs. Carnitine/organic cation transporter OCTN1 is functionally expressed in brain neurons, and transports various organic cations including the food-derived antioxidant ergothioneine and the neurotransmitter acetylcholine. The aim of the present study is to examine possible involvement of OCTN1 in epilepsy to find a target for its treatment. The γ-aminobutyric acid (GABA) receptor antagonist pentylenetetrazole (PTZ) was administrated to wild-type or *octn1* gene knockout (*octn1*^*-/-*^) mice, and then severity of seizure and PTZ concentration in the body were evaluated by behavioral observation and LC-MS/MS, respectively. *octn1*^*-/-*^ mice showed lower seizure score and higher survival rate compared to wild-type mice, whereas tissue concentrations of PTZ was almost the same between the two strains. To clarify the mechanism underlying the attenuation of PTZ-induced seizure in *octn1*^*-/-*^ mice, we examined the difference in expression of GABA receptor subunits, efficacy of the GABA receptor agonist pentobarbital or diazepam, and release of GABA into the synaptic cleft, between wild-type and *octn1*^*-/-*^ mice. Expression of GABA receptor subunits mRNA in cerebral cortex and hippocampus, and sleep latency and sleeping time induced by the GABA agonists were almost the same between the two strains. The measurement of GABA concentration in brain interstitial fluid with microdialysis showed no significant difference at steady-state between the two strains, whereas the increase in GABA by treatment with high potassium in *octn1*^*-/-*^ mice tended to be more rapid than that in wild-type mice. These results suggest that OCTN1 may positively regulate PTZ-induced seizure via the mechanism different from pharmacokinetic regulation or modulation of GABA receptor function, supporting necessity of further studies to establish OCTN1 as a target molecule of anticonvulsant.
